菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics


Contact Us


Bispecific Antibody Discovery Services

Bispecific and Multispecific Antibody Discovery Through Rational Design, Engineering, and Optimization

WuXi Biologics provides one-stop bispecific antibody discovery services to help teams design, engineer, and optimize next-gen biologics. From format selection and data-driven optimal pairing screening to early developability assessment and functional characterization, we support diverse bispecific and multispecific antibody projects across oncology, autoimmune disease, inflammation, and other therapeutic areas. Whether you are selecting formats and pairs, optimizing molecular attributes, or addressing manufacturability and scale-up challenges, our bsAb discovery services are designed to help move your programs forward with greater confidence to CMC development.

Speak with our experts about bispecific antibody discovery strategies that meet your project needs.

Speak with Our Bispecific Discovery Team

 

Core Strenght

Bispecific Antibody Discovery Services Highlights:

One-stop discovery support

From target strategy to preclinical candidate selection

Complex format expertise

Bispecific, multispecific, and immune engager support

HTP to scalable production

Rapid screening with downstream readiness

Developability-led decisions

Early stability and manufacturability risk review

Expert Design to Optimization

From rational format design & selection and pair screening to lead optimization

Diverse Format Expertise

Fit-for-purpose strategies across a wide range of bispecifics and multispecifics

Early Risk Mitigation

Early developability and functional data to support lead optimization and reduce downstream risks

HTP to Gram-Level Production

>98% heterodimer with low endotoxin to support screening, testing, and downstream studies


~11,000

bsAbs produced annually

~14,000

molecules tested by LC-MS annually

~200

bsAbs advanced to CMC

End-to-End Support

End-to-End Support for Bispecific and Multispecific Antibody Discovery

With deep expertise in bsAb discovery, our one-stop discovery workflow supports target biology analysis, format design & selection, engineering, early developability assessment, and mechanism-driven functional evaluation. Throughout the project, dedicated scientists with drug development experience provide end-to-end technical support, enabling efficient progression from concept to well-characterized preclinical candidates with reduced risk.

↔ Hover over each card to reveal details

01

Bispecific Antibody Discovery

↔ Flip for details

  • Target biology assessment and MOA alignment to guide discovery strategy
  • Biology-guided platform selection based on modality, target, and therapeutic goals
  • Humanization, affinity maturation, and Fc engineering to optimize binding, developability, and function
02

Format Design & Selection

↔ Flip for details

  • Case-specific strategies like TCE design & engineering to improve efficacy and reduce risks
  • Format selection based on affinity, avidity, epitope, and geometry
  • Assessment of PK, efficacy, safety, manufacturability, and production complexity
03

Pair Screening

↔ Flip for details

  • HTP, double-tag production workflows for diverse bispecific formats yielding 1–7 mg in 3–4 weeks
  • Tagless true four-chain bsAb production to support ADC conjugation and in vivo studies
  • Dual binding and cell-based functional assays to rank and identify optimal pairs early
04

Early Developability Assessment for Lead Optimization

↔ Flip for details

  • HTP, low material in vitro assays for early-stage antibody developability assessment
  • Fit-for-purpose panels assessing sequence liability, PK, biophysical stability, and manufacturability
  • Data-driven insights to reduce downstream risks and support confident lead optimization
05

Early Function Assessment for Lead Optimization

↔ Flip for details

  • MOA-driven in vitro assay design across biochemical, cellular, immune, and Fc effector functions
  • T-cell killing/activation and cytokine release assays for TCE characterization
  • NHP PK/PD/Tox study support in 6–11 weeks without scheduling delays
06

Production Support Throughout the Workflow

↔ Flip for details

  • Parental antibody production to support early discovery
  • High-throughput bsAb production for format selection and pair screening
  • Purification scouting with >98% heterodimer purity and <0.2 EU/mg endotoxin

Case Studies

Case Studies: Supporting Bispecific Antibody Discovery from Design to Optimization

TCR Affinity Maturation & TCR-TCE Production with Functional Characterization

This case study shows that affinity maturation improved TCR binding affinity by ~10,000-fold via HTP SPR Koff ranking, followed by transient CHO production of the TCR-TCE achieving high titer and high purity. The one-stop workflow supports rapid generation of potent building blocks for TCR-TCE discovery.

TCR Affinity Maturation & TCR-TCE Production

Eliminating Precipitation Through Structure-Guided Bispecific Antibody Engineering & Developability Assessment
+

This case study shows how early developability assessment helped identify key risks in a bispecific antibody. Initial testing revealed aggregation and precipitation issues. After structure-guided sequence optimization, the improved bsAb showed higher thermal stability while maintaining binding and biological activity.

Eliminating Precipitation Through Structure-Guided Bispecific Antibody Engineering

Anti-HSA VHH Enabling Half-Life Extension for Bispecific T-Cell Engager in Mouse PK Studies
+

This case study evaluates integration of an anti-HSA VHH molecule into a bispecific T-cell engager, extending exposure in a mouse model. ELISA measurements showed extended half-life comparable to a benchmark bsAb. The workflow provides a practical framework for BiTE discovery with improved PK performance.

Anti-HSA VHH Enabling Half-Life Extension for Bispecific T-Cell Engager

Why WuXi Biologics

Why Work with WuXi Biologics for Bispecific Antibody Discovery

  • Biology-Driven Discovery: MOA-guided support for bispecific and multispecific antibody discovery
  • Expert Strategies & Input: From rational format design and pair screening to lead optimization
  • Early Developability & Function Assessment: Generate actionable data to guide optimization and reduce downstream risks
  • HTP to Gram-Scale Production: Reliable material generation with >98% heterodimer and EU/mg endotoxin

Advance Your Next Bispecific Discovery Program with Confidence

From early discovery strategy to lead optimization support, our team works closely with clients to design fit-for-purpose workflows aligned with their biology, modality, and development goals. Contact us to discuss your bispecific or multispecific antibody project and see how WuXi Biologics can help accelerate your path to the next milestone.

Discuss Your Bispecific Antibody Projects Today

We respond within one business day.